Pharma: Biontech steckt mitten im großen Umbau – Das sind die Herausforderungen für den neuen Chef
Guido Oelkers führt bisher ein schwedisches Pharmaunternehmen und wechselt Anfang 2027 als Konzernchef zu Biontech. Er hat viel Erfahrung in der Branche.
Biontech appoints Guido Oelkers as new CEO as company embarks on major restructuring. Oelkers, previously CEO of Swedish pharmaceutical company Swedish Orphan Biovitrum (Sobi), will take over as Biontech's executive board chairman in early February 2027. In reaction to the news, Sobi shares experienced a slight decline, dropping nearly five percent.
Oelkers will succeed Uğur Şahin and Özlem Türeci, who co-founded Biontech in 2008 and announced their departure from the company in March 2026. The duo plans to establish a new enterprise. Oelkers has been the CEO of Sobi since 2017, during which he expanded the pipeline in later development stages and quadrupled revenue from 2017 to 2026.
With 30 years of experience in biotechnology and pharmaceutical industries across Europe and Asia-Pacific, Oelkers has held multiple executive positions and focuses on the introduction and marketing of innovative medications, with a particular emphasis on the US market.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
